Medical AI Alliance
← Company Index
Medical DevicesKOSDAQ 24182061 approvals

PCL. Inc

Official website

KOSDAQ-listed IVD company using SG Cap™ multiplex diagnostic technology for infectious disease, cancer, and companion animal testing.

As of 2026-10-10, PCL. Inc has 61 Korean MFDS device approvals, 14 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 2008 and listed on KOSDAQ in 2017, PCL is an in-vitro diagnostics company. Based on its SG Cap™ multiplex diagnostic technology, it manufactures and sells diagnostic kits and analyzers for infectious diseases (HIV/HBV/HCV), cancers (pancreatic, colorectal, liver, prostate, ovarian), COVID-19, influenza (flu/RSV), and autoimmune disease, as well as diagnostic kits for companion animals (dogs and cats). Since 2024 it has begun supplying medications for chronic disease management and has expanded into antibacterial additive film materials and cosmetics based on its transparent polymer material technology.

Products & technology

  • SG Cap™ multiplex diagnostic platformhigh-risk infectious disease (HIV/HBV/HCV) diagnostics
  • cancer diagnostic kitspancreatic, colorectal, liver, prostate, ovarian cancer diagnostics
  • COVID-19/influenza diagnostic kitsCOVID-19, influenza, RSV diagnostics
  • companion animal diagnostic kitscanine and feline disease diagnostics

Regulatory approvals

data.go.kr

61 Korean MFDS device approvals · 2014–2026

  • MFDSIVD reagents for inflammatory tests2026-04-16
    Product approval · Class 2체외 제인 26-4336 호
  • MFDSFlow cytometry2026-03-11
    Product approval · Class 1체외 제신 26-304 호
  • MFDSEndoscopic dilator, cavity2025-07-08
    Product approval · Class 1제신 25-869 호
  • MFDSIVD reagents for fecal occult blood test2024-12-20
    Product approval · Class 2체외 제인 24-1173 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2024-12-06
    Product approval · Class 3체외 제허 24-861 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2024-08-13
    Product approval · Class 3체외 제허 24-544 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2024-08-13
    Product approval · Class 3체외 제허 24-543 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological method2024-06-21
    Product approval · Class 3체외 제허 24-416 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2024-06-10
    Product approval · Class 3체외 제허 24-390 호
  • MFDSIVD reagents for diabetes mellitus2023-12-27
    Product approval · Class 2체외 수인 23-4937 호
  • MFDSIVD reagents for diabetes mellitus2023-12-22
    Product approval · Class 2체외 수인 23-4928 호
  • MFDSIVD Reagents for thyroid function hormone tests2023-12-11
    Product approval · Class 2체외 수인 23-4902 호
Show 49 more
  • MFDSIVD Reagents for thyroid function hormone tests2023-11-03
    Product approval · Class 2체외 수인 23-4842 호
  • MFDSClinical IVD strip for protein/lipid strip2023-10-24
    Product approval · Class 2체외 수인 23-4812 호
  • MFDSOther Reagents, classⅡ, for clinical chemistry2023-10-24
    Product approval · Class 2체외 수인 23-4811 호
  • MFDSOther Reagents, classⅡ, for clinical chemistry2023-10-18
    Product approval · Class 2체외 수인 23-4804 호
  • MFDSreagents for clinical enzymes2023-09-04
    Product approval · Class 2체외 수인 23-4749 호
  • MFDSChemiluminescence assay(CLIA) analyzer2023-08-16
    Product approval · Class 1체외 수신 23-1995 호
  • MFDSIVD Reagents for thyroid function hormone tests2023-08-11
    Product approval · Class 2체외 수인 23-4719 호
  • MFDSIVD reagents for tumor marker2023-06-26
    Product approval · Class 3체외 제허 23-714 호
  • MFDSIVD reagents for tumor marker2023-06-26
    Product approval · Class 3체외 제허 23-713 호
  • MFDSDry type clinical chemistry automated analyzer2023-04-04
    Product approval · Class 1체외 수신 23-872 호
  • MFDSChemiluminescence assay(CLIA) analyzer2022-10-06
    Product approval · Class 1체외 수신 22-1702 호
  • MFDSIVD reagent for infectious disease, immunological methodRevoked2022-04-29
    Product approval · Class 3체외 제허 22-275 호
  • MFDSTool for specimens2022-02-16
    Product approval · Class 1수신 22-239 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological method2022-02-15
    Product approval · Class 3체외 제허 22-103 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological method2022-02-15
    Product approval · Class 3체외 제허 22-101 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological methodRevoked2021-08-12
    Product approval · Class 3체외 제허 21-688 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological methodRevoked2021-06-23
    Product approval · Class 3체외 제허 21-514 호
  • MFDSTool for specimensRevoked2021-04-23
    Product approval · Class 1수신 21-697 호
  • MFDSIVD reagents for extracting nucleic acidsRevoked2021-01-22
    Product approval · Class 1체외 제신 21-84 호
  • MFDSSpecimen transport media2021-01-21
    Product approval · Class 1체외 제신 21-80 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological method2020-12-18
    Product approval · Class 3체외 제허 20-1102 호
  • MFDSIVD reagents for tumor marker2020-12-11
    Product approval · Class 3체외 제허 20-1070 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2020-12-09
    Product approval · Class 3체외 제허 20-1059 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2020-11-10
    Product approval · Class 3체외 제허 20-949 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2020-07-17
    Product approval · Class 3체외 제허 20-582 호
  • MFDSIVD reagents for extracting nucleic acids2020-07-06
    Product approval · Class 1체외 제신 20-1031 호
  • MFDSImmunoabsorbance analyzer2020-06-29
    Product approval · Class 1체외 제신 20-986 호
  • MFDSIVD reagents for tumor marker2020-04-28
    Product approval · Class 3체외 제허 20-339 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological method2020-03-30
    Product approval · Class 3체외 제허 20-229 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological method2020-03-30
    Product approval · Class 3체외 제허 20-228 호
  • MFDSFluorimetric immunoassay analyzer(FIA), stationary2020-03-19
    Product approval · Class 1체외 제신 20-366 호
  • MFDSFluorimetric immunoassay analyzer(FIA), stationary2020-03-11
    Product approval · Class 1체외 제신 20-326 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), molecular diagnostics2020-03-03
    Product approval · Class 3체외 제허 20-151 호
  • MFDSFluorimetric immunoassay analyzer(FIA), stationary2020-02-25
    Product approval · Class 1체외 제신 20-225 호
  • MFDSIVD reagents for tumor marker2020-02-18
    Product approval · Class 3체외 제허 20-126 호
  • MFDSIVD reagents for diagnosis of HIV, HBV, HCV, HTLV, immunological method2020-02-18
    Product approval · Class 4체외 제허 20-125 호
  • MFDSFluorimetric immunoassay analyzer(FIA), stationary2019-11-15
    Product approval · Class 1체외 제신 19-1492 호
  • MFDSFluorimetric immunoassay analyzer(FIA), stationary2018-05-10
    Product approval · Class 1체외 제신 18-571 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological method2018-04-06
    Product approval · Class 3체외 제허 18-235 호
  • MFDSIVD reagents for diagnosis of HIV, HBV, HCV, HTLV, immunological method2018-03-05
    Product approval · Class 4체외 수허 18-81 호
  • MFDSIVD reagents for diagnosis of HIV, HBV, HCV, HTLV, immunological method2018-03-05
    Product approval · Class 4체외 수허 18-80 호
  • MFDSFluorimetric immunoassay analyzer(FIA), stationaryRevoked2018-01-24
    Product approval · Class 1체외 제신 18-89 호
  • MFDSImmunoabsorbance analyzer2017-12-22
    Product approval · Class 1체외 제신 17-1437 호
  • MFDSIVD reagents for infectious disease marker(Diagnosis of Sexually transmitted disease, Legally designated infectious pathogens other than ‘high risk pathogens’, Infectious agents with moderate infectivity), immunological method2017-09-15
    Product approval · Class 3체외 제허 17-715 호
  • MFDSFluorimetric immunoassay analyzer(FIA), stationary2017-09-14
    Product approval · Class 1체외 제신 17-1079 호
  • MFDSFluorimetric immunoassay analyzer(FIA), stationary2017-01-25
    Product approval · Class 1체외 제신 17-84 호
  • MFDSIVD reagents for diagnosis of HIV, HBV, HCV, HTLV, immunological method2016-10-26
    Product approval · Class 4체외 제허 16-778 호
  • MFDSFluorimetric immunoassay analyzer(FIA), stationary2016-08-29
    Product approval · Class 1체외 수신 16-2242 호
  • MFDSIVD reagents for diagnosis of HIV, HBV, HCV, HTLV, immunological methodRevoked2014-05-14
    Product approval · Class 4체외 제허 14-1027 호

Key disclosures

KRX KIND via OpenDART
Show 144 more events

Publications

PubMed · affiliation-matched
Show 4 more publications

Patents

KIPRIS · applicant-matched
Show 6 more patents

AI reads

MAA server logs · IP-verified
130
Times AI engines pulled PCL. Inc's records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

1
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

129
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

8
live 1
Last 7 days
97
live 1
Last 30 days
130
live 1
All time
  • OpenAIChatGPT-Userlive1
  • OpenAIOAI-SearchBot94
  • GoogleGoogleOther27
  • PerplexityPerplexityBot5
  • AnthropicClaudeBot2
  • MicrosoftBingbot1

Measured since Aug 27, 2026 · 5 AI engines · last read Oct 8, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for PCL. Inc and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview · R&D. Send us materials and we will add them

Companies approved for the same productsMedical Devices

Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.

GC Medical Science Corporation18 shared

GC Medical Science Corporation, KOSDAQ-listed since 2014, operates diagnostic reagent, blood glucose, and hemodialysis solution businesses.

Boditech Med Inc.17 shared

KOSDAQ-listed point-of-care immunodiagnostics company supplying diagnostic cartridges and the ichroma/AFIAS instrument series.

SD BIOSENSOR INC.16 shared

KOSPI-listed in-vitro diagnostics company known for the STANDARD Q antigen/antibody test kits.

OSANG HEALTHCARE CO.,LTD.14 shared

Founded 1996, listed on KOSDAQ in 2024, OSANG HEALTHCARE develops and sells biochemistry, immunodiagnostic, and molecular IVD products.

NanoenTek,Inc.12 shared

Founded in 1987 and listed on KOSDAQ in 2000, NanoenTek develops Lab-On-a-Chip in-vitro diagnostic devices and life science instruments.

HUMASIS CO., LTD.12 shared

KOSDAQ-listed IVD company producing COVID-19 and HIV point-of-care diagnostic reagents alongside rubber products and entertainment businesses.

Precision Biosensor Inc.12 shared

KOSDAQ-listed IVD company producing time-resolved fluorescence immunodiagnostic products under the Exdia TRF brand.

Sugentech, Inc.11 shared

Founded in 2011 and KOSDAQ-listed in 2019, Sugentech develops multiplex immunoblot, point-of-care, and digital healthcare diagnostics.

Access Bio, Inc.11 shared

Founded in 2002 and KOSDAQ-listed in 2013, Access Bio develops rapid diagnostic tests for malaria, COVID-19, and other infectious diseases.

DONG-A ST CO.,LTD11 shared

Dong-A ST, spun off from Dong-A Socio Holdings in 2013 and KOSPI-listed, makes prescription drugs like Growtropin, Stillen, and Bacchus.

CALTH. Inc10 shared

Holds manufacturing approvals for 42 point-of-care diagnostic reagents and devices in the IVD market.

RollingStone Co., Ltd.7 shared

KOSDAQ-listed in-vitro diagnostics company developing the LabChip-based VERI-Q molecular diagnostic device series.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition